Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and/or mirabegron for refractory daytime urinary incontinence : A retrospective cohort study
© 2021 Wiley Periodicals LLC..
AIMS: To investigate if children with daytime urinary incontinence (DUI) and overactive bladder (OAB) refractory to standard urotherapy and medicinal treatment, would experience improvement in symptoms after add-on treatment with transcutaneous electrical nerve stimulation (TENS).
METHODS: Children were retrospectively enrolled from tertiary referral centers at Aarhus and Aalborg University Hospitals. All data were retrieved from the patients' journals. All children were prescribed TENS as an add-on treatment to the highest-tolerable dose of medicinal treatment in a standardized regime of 2 h a day for around 3 months. Primary endpoints were the number of wet days per week (WDPW) and incontinence episodes per day. Effect of treatment was defined as greater or equal to 50% reduction in the frequency of DUI episodes. Secondary endpoints were to establish predictive factors for the effect of treatment using logistic regression.
RESULTS: Seventy-six children diagnosed with DUI and OAB refractory to treatment with standard urotherapy and pharmacological treatment, at the age of 5-16 years were included from February 2017 to February 2020. A reduction in WDPW (from 6.31 [5.86-6.61] to 4.27 [3.45-4.90], p < 0.05) and incontinence episodes per day (from 2.45 [1.98-2.91] to 1.43 [1.07-1.80], p < 0.05) was observed. Twelve patients became completely dry. At 6 months follow-up, seven of the 12 complete responders had relapsed while five remained dry. A history of constipation before TENS was a predictor of poor treatment response (p = 0.016).
CONCLUSIONS: TENS as add-on to anticholinergic treatment seems effective in a number of children with treatment-refractory DUI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Neurourology and urodynamics - 41(2022), 1 vom: 15. Jan., Seite 275-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pedersen, Natashja [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.03.2022 Date Revised 24.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/nau.24812 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331594005 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331594005 | ||
| 003 | DE-627 | ||
| 005 | 20231225213814.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/nau.24812 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331594005 | ||
| 035 | |a (NLM)34618378 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pedersen, Natashja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transcutaneous electrical nerve stimulation as add-on therapy in children receiving anticholinergics and/or mirabegron for refractory daytime urinary incontinence |b A retrospective cohort study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.03.2022 | ||
| 500 | |a Date Revised 24.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a AIMS: To investigate if children with daytime urinary incontinence (DUI) and overactive bladder (OAB) refractory to standard urotherapy and medicinal treatment, would experience improvement in symptoms after add-on treatment with transcutaneous electrical nerve stimulation (TENS) | ||
| 520 | |a METHODS: Children were retrospectively enrolled from tertiary referral centers at Aarhus and Aalborg University Hospitals. All data were retrieved from the patients' journals. All children were prescribed TENS as an add-on treatment to the highest-tolerable dose of medicinal treatment in a standardized regime of 2 h a day for around 3 months. Primary endpoints were the number of wet days per week (WDPW) and incontinence episodes per day. Effect of treatment was defined as greater or equal to 50% reduction in the frequency of DUI episodes. Secondary endpoints were to establish predictive factors for the effect of treatment using logistic regression | ||
| 520 | |a RESULTS: Seventy-six children diagnosed with DUI and OAB refractory to treatment with standard urotherapy and pharmacological treatment, at the age of 5-16 years were included from February 2017 to February 2020. A reduction in WDPW (from 6.31 [5.86-6.61] to 4.27 [3.45-4.90], p < 0.05) and incontinence episodes per day (from 2.45 [1.98-2.91] to 1.43 [1.07-1.80], p < 0.05) was observed. Twelve patients became completely dry. At 6 months follow-up, seven of the 12 complete responders had relapsed while five remained dry. A history of constipation before TENS was a predictor of poor treatment response (p = 0.016) | ||
| 520 | |a CONCLUSIONS: TENS as add-on to anticholinergic treatment seems effective in a number of children with treatment-refractory DUI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cholinergic antagonists | |
| 650 | 4 | |a mirabegron | |
| 650 | 4 | |a overactive | |
| 650 | 4 | |a transcutaneous electrical nerve stimulation | |
| 650 | 4 | |a urge | |
| 650 | 4 | |a urinary bladder | |
| 650 | 4 | |a urinary incontinence | |
| 650 | 7 | |a Acetanilides |2 NLM | |
| 650 | 7 | |a Cholinergic Antagonists |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a mirabegron |2 NLM | |
| 650 | 7 | |a MVR3JL3B2V |2 NLM | |
| 700 | 1 | |a Breinbjerg, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Thorsteinsson, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Hagstrøm, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Rittig, Søren |e verfasserin |4 aut | |
| 700 | 1 | |a Kamperis, Konstantinos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurourology and urodynamics |d 1993 |g 41(2022), 1 vom: 15. Jan., Seite 275-280 |w (DE-627)NLM074810308 |x 1520-6777 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:275-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/nau.24812 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2022 |e 1 |b 15 |c 01 |h 275-280 | ||